Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Mario Alberto Accardi sold 15,000 shares of the firm's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $14.00, for a total value of $210,000.00. Following the completion of the transaction, the insider now owns 216,485 shares in the company, valued at $3,030,790. The trade was a 6.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Centessa Pharmaceuticals Price Performance
NASDAQ:CNTA traded down $0.77 on Wednesday, hitting $13.43. The stock had a trading volume of 779,371 shares, compared to its average volume of 729,021. The company has a fifty day moving average price of $12.76 and a two-hundred day moving average price of $14.79. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $8.46 and a 1-year high of $19.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 14.37 and a current ratio of 14.37.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.15. As a group, equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages have recently commented on CNTA. Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price for the company. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Wall Street Zen raised shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Chardan Capital started coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set a "buy" rating and a $30.00 target price on the stock. Finally, Guggenheim reaffirmed a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $27.89.
Check Out Our Latest Report on Centessa Pharmaceuticals
Institutional Investors Weigh In On Centessa Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. increased its position in shares of Centessa Pharmaceuticals by 35.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company's stock worth $99,999,000 after purchasing an additional 1,834,973 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after buying an additional 685,371 shares during the period. Janus Henderson Group PLC boosted its stake in Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock worth $82,218,000 after buying an additional 3,614,623 shares during the period. Farallon Capital Management LLC increased its position in shares of Centessa Pharmaceuticals by 24.3% during the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock valued at $58,603,000 after acquiring an additional 684,391 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock valued at $57,396,000 after acquiring an additional 710,936 shares during the period. Hedge funds and other institutional investors own 82.01% of the company's stock.
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
